EP Lab Digest - September 2007 - (Page 25)

SEPTEMBER 2007 NEWS 25 ZOLL Receives Clearance to Market AED Pro With See-Thru CPR Technology Helps Minimize Interruptions in CPR OLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, has received clearance from the U.S. Food and Drug Administration (FDA) to market and sell the ZOLL AED Pro® with See-Thru CPR™ technology. ZOLL’s patented See-Thru CPR helps minimize interruptions in CPR — one of the key recommendations of the American Heart Association’s (AHA) Guidelines for Advanced Cardiac Life Support. See-Thru CPR reduces interruptions by allowing clinicians to see organized electrical activity during CPR compressions by filtering out compression artifact (“noise”).This lets rescuers see a patient’s underlying cardiac rhythm during resuscitation efforts and eliminates the need to stop compressions to see if defibrillation was successful. The AHA notes that a primary source of interruption of CPR is stopping to determine underlying ECG rhythm. Z “This exclusive ZOLL technology allows the professional rescuer to analyze a patient’s heart rhythm while continuous CPR is in progress and monitor the heart rhythm to determine the appropriate time to analyze or stop CPR to check the ECG,” said Richard A. Packer, President and Chief Executive Officer of ZOLL. “It contributes to helping rescuers and clinicians save more lives.” See-Thru CPR will only be activated when the AED Pro is in Manual Mode.The feature will not be enabled when the AED Pro is operating in semiautomatic mode. See-Thru CPR will automatically “turn on” when the rescuer switches the unit from semi-automatic to manual, which is accomplished by depressing two soft keys. The AED Pro is the first defibrillator designed for professional responders with instantaneous feedback on CPR chest compressions. Its real-time feedback, Real CPR Help™, includes a metronome set at the AHA-recommended 100 beats per minute and a screen display, which helps rescuers achieve the optimum rate and depth of compression levels through audible and/or visual prompts. All CPR data can be recorded and reviewed using RescueNet™ Code Review software. It also features a high-resolution ECG display, Lead II monitoring, and unrivaled battery compatibility. Its rugged construction and exceptional durability support the needs of both Basic Life Support and Advanced Life Support professionals in hospitals and emergency services. Sudden cardiac arrest is the leading cause of unexpected death in the world and strikes without warning. In the U.S. alone, there are more than 325,000 deaths each year from cardiac arrest. Currently, only about six percent of victims survive. St. Jude Medical Receives FDA Clearance for ACross Transseptal Access System New Device Increases Control and Reduces Complexity of Critical Step in Accessing the Left Atrium t. Jude Medical, Inc. announced U.S. Food and Drug Administration (FDA) clearance and a Health Canada License for the ACross ™ Transseptal Access System, a device that improves control and simplifies the procedure physicians use to access the left atrium during complex cardiac procedures such as atrial fibrillation ablation. The device is used to reach the left atrium of the heart, which is difficult to access but where some of the most complex arrhythmias occur. The device was first used at Southlake Regional Health Centre in S Newmarket, Ontario by Atul Verma, MD, and Yaariv Khaykin, MD. “The ACross System brings consistency and simplicity to a procedure which can be complex and challenging,” said Dr. Khaykin. “While ACross uses techniques and approaches that have been employed by EPs for many years, its enhanced tools simplify the procedure and add safeguards for some of the most critical steps.” The ACross Transseptal Access System consolidates the sheath, dilator and needle into a single interlocking handle for greater control over the system’s components and more intuitive positioning within the heart. The device’s handle allows the components to fit precisely together, ensuring that the puncture needle is not deployed until the physician is confident in its location, and that it is only advanced a pre-determined distance. Also, the ergonomic design incorporates a directional fin, or ridge, on the handle, so that the physician will intuitively know the orientation of the needle and sheath tip within the heart. Because there is no direct path to the left atrium to deliver therapy, EPs use a long, curved needle to puncture the septum, or wall, between the left and right atrium and pass a sheath into the left chamber. The process of making this puncture and creating a conduit to the left atrium is called a transseptal procedure. Traditional transseptal tools require clinicians to simultaneously manipulate a separate needle, dilator, and sheath, maintaining precise distances between each component and their angles relative to the patient’s anatomy. This complex procedure may often require two or more people to manipulate the various components to prevent potential complications due to inadvertent needle deployment or improper orientation.

Table of Contents Feed for the Digital Edition of EP Lab Digest - September 2007

The ICD Shock and Stress Management Program: Interview with Samuel F. Sears Jr., PhD Universal ECG Screening: The Advocate’s Perspective Contents Letter from the Editor Spotlight Interview: Morristown Memorial Hospital 10-Minute Interview: About the Mended Hearts and Mended Little Hearts Organizations ICD Patient Support Groups Email Discussion Group: September 2007 Technology: Only As Good As the Attitude Behind It! Electrophysiologic Management and Treatment of Chronic and Acute Cardiac Device Infection First Annual EP Lab Digest Salary Survey Events Calendar Industry News and Products

EP Lab Digest - September 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.